AGEN Agenus Inc

USD 0.68 0.00 0
Icon

Agenus Inc (AGEN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.68

0.00 (0.00)%

USD 0.26B

7.43M

N/A

N/A

Icon

AGEN

Agenus Inc (USD)
COMMON STOCK | NSD
USD 0.68
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.26B

N/A

USD 0.68

Agenus Inc (AGEN) Stock Forecast

N/A

Based on the Agenus Inc stock forecast from 0 analysts, the average analyst target price for Agenus Inc is not available over the next 12 months. Agenus Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Agenus Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Agenus Inc’s stock price was USD 0.68. Agenus Inc’s stock price has changed by +4.12% over the past week, +15.61% over the past month and -65.55% over the last year.

No recent analyst target price found for Agenus Inc
No recent average analyst rating found for Agenus Inc

Company Overview Agenus Inc

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal an...Read More

https://www.agenusbio.com

3 Forbes Road, Lexington, MA, United States, 02421-7305

533

December

USD

USA

Adjusted Closing Price for Agenus Inc (AGEN)

Loading...

Unadjusted Closing Price for Agenus Inc (AGEN)

Loading...

Share Trading Volume for Agenus Inc Shares

Loading...

Compare Performance of Agenus Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AGEN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Agenus Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD90.49B 26.38 17.57

ETFs Containing AGEN

Symbol Name AGEN's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Agenus Inc (AGEN) Stock

Stock Target Advisor's fundamental analysis for Agenus Inc's stock is Bearish.

Unfortunately we do not have enough data on AGEN's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AGEN's stock to indicate what its average analyst target is.

AGEN stock's Price/Earning ratio is 8.20. Our analysis grades AGEN stock's Price / Earning ratio at F. This means that AGEN stock's Price/Earning ratio is above 53% of the stocks in the Biotechnology sector in the NSD exchange. Based on this AGEN may be a overvalued for its sector.

The last closing price of AGEN's stock was USD 0.68.

The most recent market capitalization for AGEN is USD 0.26B.

Unfortunately we do not have enough analyst data on AGEN's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Agenus Inc's stock.

As per our most recent records Agenus Inc has 533 Employees.

Agenus Inc's registered address is 3 Forbes Road, Lexington, MA, United States, 02421-7305. You can get more information about it from Agenus Inc's website at https://www.agenusbio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...